MK-7625A Plus Metronidazole Versus Meropenem in Pediatric Participants With Complicated Intra-Abdominal Infection (cIAI) (MK-7625A-035)

NCT03217136 PHASE2 COMPLETED Results posted

This study aims to evaluate the safety and tolerability of MK-7625A (ceftolozane/tazobactam) plus metronidazole, compared with that of meropenem in pediatric participants with cIAI.

Details

Lead sponsor	Merck Sharp & Dohme LLC
Phase	PHASE2
Status	COMPLETED
Enrolment	94
Start date	Tue Apr 03 2018 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Mon Mar 16 2020 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

• Complicated Intra-Abdominal Infection

Interventions

• Ceftolozane/Tazobactam
• Metronidazole
• Meropenem
• Placebo for Metronidazole

Countries

South Africa, Russia, Malaysia, Ukraine, Hungary, Mexico, Romania, Lithuania, Spain, United States, Turkey (Türkiye), Brazil